Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06892548 · ClinicalTrials.gov registry record · Phase 1

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

A Phase 1 study of Advanced Lung Cancer, sponsored by BioNTech SE.

Recruiting
Registry status
Phase 1
Development phase
594
Enrollment target
20
Study locations

NCT06892548: Recruiting Phase 1 study of Advanced Lung Cancer, sponsored by BioNTech SE.

NCT06892548 is a Phase 1 study of Advanced Lung Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 594 participants, above the 277-participant average among 3 other Advanced Lung Cancer trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06892548, a Phase 1 study of Advanced Lung Cancer, is actively recruiting participants, sponsored by BioNTech SE.

RECRUITING
Registry status
Phase 1
Development phase
594 participants
Enrollment target
20
Study locations

Study Summary

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Conditions Studied

Advanced Lung Cancer

Interventions

  • BIOLOGICAL BNT324
  • BIOLOGICAL BNT327

Study Locations (20)

California

  • Precision NextGen Oncology and Research Center - Beverly Hills
  • Cedars Sinai Medical Center - Los Angeles
  • UCLA - David Geffen School of Medicine - Santa Monica

Texas

  • Texas Oncology - DFW - Dallas
  • MD Anderson Cancer Center - Houston
  • Texas Oncology - Northeast - Tyler

Victoria

  • Bendigo Hospital - Bendigo
  • Barwon Health - Geelong
  • Sunshine Hospital - Saint Albans

New York

  • Memorial Sloan Kettering Cancer Center (MSKCC) - New York
  • Icahn School of Medicine at Mount Sinai PRIME - New York

Arizona

  • Mayo Clinic Arizona - Phoenix

Florida

  • Mayo Clinic in Florida - Jacksonville

Iowa

  • University of Iowa Hospitals & Clinics PARENT - Iowa City

Minnesota

  • Mayo Clinic-Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 594 participants
Start Date 2025-05-02
Est. Completion 2031-06
Phase Phase 1
BioNTech SE

53 total trials

What NCT06892548 shows while recruiting

NCT06892548 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 277-participant average among 3 other Advanced Lung Cancer trials with a reported enrollment target (114% higher).

The record links to 1 condition, with Advanced Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which BNT324 is the first listed.

NCT06892548 names 20 study sites across 13 states, led by California, Texas, Victoria.

Frequently Asked Questions

What is clinical trial NCT06892548 about?

NCT06892548 is a clinical study titled "A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer". This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer ...

What is the current status of trial NCT06892548?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 594 participants. The study started on 2025-05-02. Estimated completion is 2031-06.

What conditions does trial NCT06892548 study?

This clinical trial studies the following conditions: Advanced Lung Cancer.

What interventions are being tested in trial NCT06892548?

The interventions under investigation include: BNT324 (BIOLOGICAL), BNT327 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06892548?

This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06892548 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04701684 · 594 participants · NA

    WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

  • NCT05491213 · 594 participants · NA

    TELESCOPE- TELEhealth Shared Decision-making COaching

  • NCT05867420 · 594 participants · Phase 1

    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

  • NCT06890884 · 594 participants · Phase 2

    A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06892548

Source: ClinicalTrials.gov NCT06892548, the US trial registry maintained by the National Library of Medicine. NCT06892548 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.